Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Vastarel

(Trimetazidine)

ApprovedSmall molecule

IIRCCS San Raffaele

Trimetazidine is used to treat angina (chest pain caused by reduced blood flow to the heart) and helps improve heart function in patients with heart disease by changing how heart cells use energy.[2] Vastarel is currently approved and in use across 20 indications[4].[1]

Vastarel is one of 503 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.

20

Indications

22

Total Trials

0

Active Trials

502

Competitors

Pipeline

Status by Indication[4][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Cardiovascular DiseaseUnknown

Peripheral NeuropathyActive, not recruiting

Angina PectorisUnknown

Acute-on-Chronic Liver FailureActive, not recruiting

Diabetic NephropathyActive, not recruiting

Paroxysmal Atrial FibrillationActive, not recruiting

Myocardial InfarctionActive, not recruiting

Chronic Liver FailureActive, not recruiting

AmyloidosisActive, not recruiting

Coronary Artery DiseaseApproved

Active, not recruiting

Cardiovascular DiseasePreclinical

Unknown

Peripheral NeuropathyPhase 1

Active, not recruiting

Angina PectorisPreclinical

Unknown

Acute-on-Chronic Liver FailurePhase 1

Active, not recruiting

Diabetic NephropathyPhase 2

Active, not recruiting

Paroxysmal Atrial FibrillationPreclinical

Active, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Chronic Liver FailurePhase 1

Active, not recruiting

AmyloidosisApproved

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Vastarel

IIRCCS San Raffaele

Spikevax

Bnt162b2

COVID-19 Vaccine

Biaxin

Aldactone

Nexavar

Stivarga

Aimovig

Singulair

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Disease3 trials

Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease

Completed·IIRCCS San Raffaele·Phase 4·NCT00282360·30 enrolled

Cardiac Metabolic Modulator Treatment for Improvement of Diastolic Function in Patients With Coronary Heart Disease

Unknown status·CChina National Center for Cardiovascular Diseases·Phase 4·NCT03887013·226 enrolled

Metoprolol and Trimetazidine for Coronary Heart Disease With Angina

Completed·SShiyan City Renmin Hospital·N/A·NCT07074834·102 enrolled

Coronary Artery Disease2 trials

Effect of Trimetazidine on the Improvement of Coronary Microvascular Dysfunction in Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease)

Unknown status·SShanghai 10th People's Hospital·N/A·NCT03504202·10 enrolled

The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease

Completed·—·Phase 4·NCT02107144·71 enrolled

Myocardial Infarction1 trial

Effect of Trimetazidine During the Primary PCI on Cardiac Function in Patients With ST-elevation Myocardial Infarction

Unknown status·—·N/A·NCT02826616·240 enrolled

Chronic Liver Failure1 trial

TRimetazidine for acUte on Chronic Liver Failure STudy

Suspended·UUnknown Sponsor·Phase 1·NCT03737448·30 enrolled

Ischemic stroke1 trial

"The Effect of Trimetazidine on the Clinical Outcome of Acute Ischemic Stroke Patients"

Completed·—·Phase 3·NCT06656442·60 enrolled

14 more indications

Diabetic Nephropathy1 trial

The Effects of TMZ on Diabetic Nephropathy

Unknown status·TTongji Hospital·Phase 2·NCT05147194·150 enrolled

Hypertension1 trial

Trimetazidine in Pulmonary Artery Hypertension

Unknown status·PPontificia Universidad Catolica de Chile·Phase 2·NCT02102672·25 enrolled

Amyloidosis1 trial

The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed With Wild-Type Transthyretin Cardiac Amyloidosis

Completed·SSteen Hvitfeldt Poulsen·Phase 4·NCT05633563·24 enrolled

Injury1 trial

Trimetazidine in Myocardial Injury After Percutaneous Coronary Intervention in Patients With Angina and Diabetes

Unknown status·UUniversity of Sao Paulo General Hospital·Phase 3·NCT03715582·120 enrolled

Tolerance1 trial

Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI

Completed·SShenyang Northern Hospital·Phase 4·NCT03809273·681 enrolled

Acute Kidney Injury1 trial

Allopurinol and Trimetazidine as a Preventive of Acute Kidney Injury in PCI Patients

Unknown status·—·Phase 4·NCT05540184·124 enrolled

Rehabilitation1 trial

Efficacy of Personalized Exercise Program and Trimetazidine in Rehabilitation of Patients After RFA of AF

Completed·NNational Research Center for Preventive Medicine·N/A·NCT04511520·72 enrolled

Clopidogrel1 trial

Trimetazidine as an Adjunct to Enhance Clopidogrel Response.

Completed·TThe University of The West Indies·Phase 2·NCT03603249·24 enrolled

COVID-191 trial

Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19

Unknown status·MMinistry of Health, Brazil·Phase 2·NCT04760821·80 enrolled

Pulmonary Arterial Hypertension1 trial

The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension

Completed·IIndonesia University·Phase 2/3·NCT03273387·26 enrolled

Radiotherapy1 trial

Effect of Trimetazidine on Radiotherapy-induced Heart Damage.

Unknown status·PPeking University Third Hospital·Phase 2/3·NCT04939857·80 enrolled

Hypertrophic Cardiomyopathy1 trial

Trimetazidine Therapy in Hypertrophic Cardiomyopathy

Unknown status·UUniversity College, London·Phase 2·NCT01696370·90 enrolled

MASLD1 trial

Benefits of Trimetazidine in MASLD Patients

Completed·OOctober 6 University·Phase 2·NCT06140953·60 enrolled

Peripheral Neuropathy1 trial

Trimetazidine Efficacy in Attenuating Paclitaxel-Induced Peripheral Neuropathy

Completed·MMinia University·Phase 1/2·NCT06459193·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for Trimetazidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Vastarel drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Trimetazidine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Trimetazidine. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — IRCCS San Raffaele company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: IIRCCS San Raffaele

Related News